MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Bone Sarcoma. According to GlobalData, Phase I drugs for Bone Sarcoma have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MASCT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MASCT overview

Cellular immunotherapy is under development for the treatment of soft tissue sarcoma including leiomyosarcoma, liposarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath, fibrosarcoma, pleomorphic rhabdomyosarcoma, endometrial stromal sarcoma, desmoplastic small round cell tumor, bladder cancer, osteosarcoma, pancreatic cancer, nasopharyngeal cancer, urothelial cell carcinoma, bile duct cancer (cholangiocarcinoma), bladder cancer, ureter cancer, renal cell cancer and urethral cancer. It is administered as intravenous drip and through subcutaneous route. The therapeutic candidate constitutes autologous dendritic cells loaded with antigens called as multiple antigens specific cellular therapy (MASCT). It was also under development for hepatocellular carcinoma, gastric cancer, gastroesophageal adenocarcinoma, triple-negative breast cancer, ovarian cancer, adenocarcinoma of the gastroesophageal junction, advanced solid tumors including lung cancer, colon cancer, prostate cancer,

Hengrui Yuanzheng Biotechnology overview

Hengrui Yuanzheng Biotechnology is a biopharmaceutical company that develops multiple product pipelines including MASCT, TCR-T double-antibody for patients with solid tumors. It is headquartered in Shanghai, China.

For a complete picture of MASCT’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 January 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.